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Clinical data in ovarian cancer indicate that resistance to chemo-
therapeutic drugs in these tumours is both intrinsic and acquired.
Taxol, etoposide, cisplatin, anthracyclines and cyclophosphamide
are currently used in treatment (Cannistra, 1993; Trimble et al,
1994). The finding of intrinsic or acquired resistance to these drugs,
which have different targets, suggests that differences in expression
levels of various resistance-associated proteins may be expected in
primary ovarian tumours. Moreover, several resistance mechanisms
may be triggered when resistance develops during chemothera-
peutic treatment (see Van der Zee et al, 1995 for review).
Recently, it was described that DNA topoisomerase II (Topo-II)
is involved in drug resistance and sensitivity in human tumours.
Two isoforms have been described (Topo-IIa and Topo-IIb). It
was shown that these DNA conformation-controlling nuclear
enzymes are the target for several drugs that are widely used in the
clinic as anti-cancer chemotherapy (Pommier, 1993). Examples of
such drugs are anthracyclines (e.g. doxorubicin) and epipodophyl-
lotoxins (e.g. etoposide). These drugs exert their action by stabi-
lizing a reaction intermediate formed during the catalytic cycle of
Topo-II. The presence of this stabilized protein–DNA complex,
which is called the cleavable complex, interferes with several
processes which take place at DNA level (transcription and repli-
cation), causing DNA damage and ultimately cell death. Topo-II-
related drug resistance is caused by a decrease in cleavable
complex formation in the nucleus, which will lead to less DNA
damage and less cell death.
In human ovarian tumours, it was found that Topo-II decatena-
tion activity increased with malignant transformation, and
decreased after first-line platinum/cyclophosphamide treatment
(Van der Zee et al, 1991, 1994a). This decrease was the more
remarkable because Topo-II is not the primary target for these
drugs. In these studies, no correlation was found between mitotic
index and Topo-II activity levels, and no evidence for an altered
(mutated) Topo-II was found. Additionally, no relation was found
between Topo-IIa or -b protein levels and Topo-II activity,
cleavable complex formation or cell cycle parameters. Recently,
Martinchick et al (1997) found that Topo-IIa protein levels (as
determined by immunohistochemistry) were increased in malig-
nant ovarian neoplasms when compared with borderline tumours.
The aim of the present study is to evaluate the regulation of
Topo-lla and b levels in untreated ovarian cancers in more detail.
Especially for Topo-IIb, only very limited data in human tumours
(and especially for ovarian cancer) are available. Topo-II mRNA
levels were determined by Northern blotting for Topo-IIa and -b,
and with a quantitative reverse transcriptase polymerase chain
reaction (RT-PCR) assay for Topo-IIa. The latter assay enables
determination of Topo-IIa mRNA levels quantitatively in small
tumour samples, and was used for the first time to determine Topo-
IIa mRNA levels in patient material. Additionally, Topo-II protein
levels were measured with Western blotting (Topo-IIa and -b) and
Topo-II activity was determined with the decatenation assay.
MATERIALS AND METHODS
Human material
Tumour specimens were obtained from patients with untreated
epithelial ovarian adenocarcinomas operated consecutively at co-
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operating hospitals in the northern part of the Netherlands in 1994.
Tumour collection was supervised by a pathologist. One part of
the tumour was embedded in paraffin for routine histology and the
other part was stored in liquid nitrogen at –180°C. For Topo-II
assays, the last sample was fractioned in liquid nitrogen and
pulverized and homogenized mechanically using a microdismem-
branator at 0°C. The powder was distributed in equal portions for
isolation of RNA and protein extracts.
Patient characteristics
All patients were staged according to the International Federation
of Obstetrics and Gynaecology (FIGO) classification. Tumours
were histologically classified according to the World Health
Organization (WHO) classification using paraffin-embedded
tissue sections (Serov et al, 1973). Carcinomas were graded into
well- (I), moderately (II), and poorly differentiated (III) adeno-
carcinomas (Sobre et al, 1982). Acetone fixated 4-mm tumour
sections from the frozen material were stained with haematoxylin
and eosin (HE) to determine the tumour volume index (TVI;
percentage of malignant tissue in tumour specimen) of the
samples. The TVI was measured by a point counting technique,
using a 42-point grid placed on a projection microscope ´200 as
described by Baak et al (1988).
Isolation of total RNA
Total RNA was isolated using a guanidine isothiocyanate/caesium
chloride method (Chirgwin et al, 1979). The quality of all RNA
samples was checked on formaldehyde-containing agarose gels.
Only RNA samples with clearly visible ribosomal bands were
used for Northern blotting, RT-PCR, Western blotting and Topo-II
activity experiments.
Northern blot analysis
RNA was vacuum slotblotted onto positively charged nylon
membranes (Hybond N+, Amersham, UK). Probes were labelled
with [32P]dCTP (3000 Ci mmol–1, Amersham) using an oligo-
labelling kit (Pharmacia, Woerden, The Netherlands). The Topo-IIa
probe SP1 was kindly provided by KB Tan (Chung et al, 1989). The
Topo-IIb probe was derived by PCR from a plasmid containing the
entire Topo-IIb cDNA sequence (pCDM8; provided by ID
Hickson). Briefly, the Topo-IIb-specific PCR primers are positioned
at bases 3675–3694 (5¢-GGAAGAGACAATGCCCTCAC-3¢), and
4756–4776 (5¢-CAGAGAAGGTGGCTCAGTAGG-3¢)
[numbering according to the EMBL DNA library (access number
X68060; see Chung et al (1989) for sequence comparisons]. Blots
were hybridized overnight at 65°C in 0.5 M disodium hydrogen
phosphate, pH 7.2, 1 mM EDTA, 7% sodium dodecyl sulphate
(SDS). Post-hybridization washes were performed in 2 ´ SSC (1 ´
SSC = 0.15 M sodium chloride, 0.015 M sodium citrate, pH
7.0)/0.1% SDS, 1 ´ SSC/0.1% SDS and 0.1 ´ SSC/0.1% SDS
respectively, at 65°C for 30 min. Membranes were exposed for at
least 5 h to Kodak X-Omat XAR radiographic film between intensi-
fying screens at –80°C.
Band intensities were quantified using the LKB Ultroscan XL
laser densitometer (Pharmacia). The blots were stripped and rehy-
bridized with a 28S rRNA probe, after which the signals were
corrected for 28S rRNA band intensities.
Topo-IIa RT-PCR
After Northern blotting, only from seven of the ten tumours with
a TVI ³ 50% was RNA available for Topo-IIa RT-PCR. The
Topo-IIa RT-PCR assay was performed as described previously
(Withoff et al, 1994). Briefly, a series of different recombinant
Topo-IIa RNA dilutions (ranging from 0.5 to 200 pg) was mixed
with 100 ng of tumour RNA containing the unknown amount of
Topo-IIa mRNA.
The recombinant Topo-IIa RNA was synthesized by in vitro
transcription of a Topo-IIa sequence containing a 78-bp insert.
Each mixture was converted into cDNA using reverse transcrip-
tase (RT) and a Topo-IIa-specific PCR primer. The recombinant
cDNA and the cellular Topo-IIa cDNA are co-amplified using the
primer mentioned before and a second Topo-IIa-specific primer.
Table 1 Clinicopathological characteristics of 15 ovarian carcinoma
samples
Tumour TVI Tumour Tumour Tumour
stage grade histology
18 5 I V I I s a
2 95 III II sa
3 85 III II ma
4 80 IIc II sa
5 80 IV III sa
6 75 III III ac
7 70 III II sa
8 65 III III sa
9 60 III III sa
10 50 III III sa
11 40 III I sa
12 30 III III sa
13 25 III II sa
14 20 III II sa
15 n.e. III III ac
Histopathological type: ac, adenocarcinoma; sa, serous adenocarcinoma;
ma, mucinous adenocarcinoma; n.e., not evaluated.
Table 2 Results obtained for 15 ovarian tumours. Shown are mRNA and
protein values and overall Topo-II activity in these tumours. Tumour 1 was
defined as the 100% value for each assay
Tumour
mRNA Protein
Activity RT-PCR
(TVI) Topo-IIa Topo-IIb Topo-IIa Topo-IIb Topo-II Topo-IIa
1 (85) 100% 100% 100% 100% 100% 100%
2 (95) 13 140 24 82 100 25
3 (85) 52 191 58 74 133 80
4 (80) 52 65 72 20 30 60
5 (80) 30 65 20 8 24 n.m.a
6 (75) 9 102 46 11 48 59
7 (70) 61 149 27 69 183 80
8 (65) 9 37 16 26 24 n.m.
9 (60) 43 140 48 37 100 n.m.
10 (50) 43 102 51 56 48 52
11 (40) 9 60 7 n.d.b 133 n.m.
12 (30) 61 167 15 3 133 n.m.
13 (25) 17 107 10 7 30 n.m.
14 (20) 117 107 109 34 n.d. n.m.
15 (n.e.c) 26 60 1 n.d. 14 n.m.
an.m., not measured; bn.d., not detectable; cn.e., not evaluated.750 S Withoff et al
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During this reaction, the recombinant and the tumour Topo-IIa
mRNA compete for the primers present. After PCR, the reaction
products can be separated on an agarose gel electrophoretically.
The signal ratio between the two PCR products is determined by
densitometry. In the lane in which the ratio is 1.0, the amount of
tumour Topo-IIa mRNA molecules present must have been equal
to the known amount of recombinant RNA which was added.
Taking into account the lengths of the recRNA and the Topo-IIa
mRNA, one can calculate the corresponding amount of Topo-IIa
mRNA in the tumour sample.
Isolation of extracts for Western blot and activity assay
purposes
Protein extracts were isolated from powdered tumour material as
previously described, using a 0.35 M sodium chloride buffer (Van
der Zee et al, 1991). Total protein concentration was determined in
a fraction of the extract with the Lowry assay (Lowry et al, 1951).
For Western blotting purposes, part of the extract was diluted 1:1
in standard Western blot sample buffer (0.5 M tris-HCl, pH 6.8, 4%
SDS, 20% glycerol, 0.002% bromophenol blue, 10% 2-mercapto-
ethanol) and stored at –80°C. The other half of the extract was
diluted 1:1 in 87% glycerol for the Topo-II activity assay.
Topo-IIa and b Western blotting
Protein (50 or 100 mg) was size fractionated by sodium dodecyl
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) (7.5%)
according to the procedure of Laemmli (1970) and blotted onto
PVDF membranes (Millipore, Etten-Leur, the Netherlands) using
a semidry blot system. Topo-IIa protein levels were determined
with a polyclonal antibody (Cambridge Research Biochemicals,
Northwich, Cheshire, UK) using the Western-Light chemilumines-
cent detection system (Tropix, Bedford, MA, USA). Topo-IIb
levels were measured with a polyclonal rabbit antibody that has
been extensively described in literature (Boege et al, 1995; Meyer
et al, 1997) and that was kindly provided by Dr F Boege
(Würzburg, Germany). Binding of this antibody was detected with
the ECL-chemiluminescence kit (Amersham, Little Chalfont,
UK). Chemiluminescence signals were visualized on Kodak X-
Omat XAR radiographic film. Quantitation was performed by
scanning autoradiographs with a LKB Ultroscan XL laser densito-
meter (Pharmacia).
As a positive control, 5 mg of GLC4 (a well-defined human small-
cell lung cancer cell line with known Topo-II mRNA and protein
levels; Versantvoort et al, 1995) protein extract was used in each blot.
Topo-II activity assay
Topo-II catalytic activity assay was performed by measurement of
decatenation of kDNA in the presence of 1 mM ATP as described
previously (De Jong et al, 1990). Nuclear extract of the well-
defined small-cell lung carcinoma cell line GLC4 was taken as a
positive control for each assay (Zijlstra et al, 1987).
Statistics
One-tailed Spearman rank correlations were computed (SPSS) to
analyse correlations (r) between mRNA and protein levels for each
isozyme.
Additionally, correlations between isozyme protein levels and
Topo-II activity were calculated. Only tumour samples with a TVI
³ 50% were used for these purposes. For seven of the tumours with
a TVI ³ 50%, correlations were computed between Topo-IIa RT-
PCR results and Topo-IIa Northern blot data, and between Topo-
IIa RT-PCR values and Topo-IIa protein levels. Additionally,
two-tailed Spearman rank correlations were calculated between
the TVI and Topo-II isozyme protein levels and between the Topo-
IIb/Topo-IIa ratio and Topo-II activity. Only P-values less than
0.05 were considered to be significant.
RESULTS
Patient characteristics
In Table 1, the clinicopathological characteristics of the 15 tumour
samples are presented. Ten tumours had a TVI ³ 50%. One tumour
was classified stage I–II and 14 tumours stage III–IV, according to
the FIGO classification.
Topo-IIa and b mRNA levels
Northern slot blotting was performed as described above (the films
are not shown). Tumour 1 was used as an internal standard. The
signals were scanned, the Topo-II/28S ratio was calculated and the
results were expressed as a percentage of the 100% value which
was given to tumour 1. In Table 2, the data obtained for all tumours
is summarized. The mean Topo-IIa mRNA level was 43%, with a
range from 9% to 117%. The mean Topo-IIb mRNA value was
106% (range 37–191%).
Topo-IIa quantitative RT-PCR
Three representative RT-PCR results are shown in Figure 1. The
results of seven tumours are presented in Table 2 and show a large
variability (mean value 65%, range 25–100%), just as was found
for the Northern blot data.
Topo-IIa and b protein levels and Topo-II activity
In Figure 2, representative Topo-IIb Western blot results are
shown (Topo-IIa blots have been shown previously; Van der Zee
et al, 1994a). In all the samples with detectable Topo-IIb protein
levels, we detected the band at 180 kDa.
Tumour 1
Tumour 4
Tumour 2
M 0.5 pg 1 pg 2 pg 5 pg 10 pg 25 pg 50 pg 100 pg150 pg200 pgM
M 0.5 pg 1 pg 2 pg 5 pg 10 pg 25 pg 50 pg 100 pg150 pg200 pgM
Figure 1 Representative Topo-IIa RT-PCR results showing tumour 1, 4 and
2 displaying high, intermediate and low Topo-IIa mRNA levels. The range of
recombinant RNA used is shown above the photographs. The recombinant
PCR product is 430 bp long; the Topo-IIa PCR product 342 bp. The
intermediate band is the result of a rec-cDNA/Topo-IIa-cDNA hybridization
(see Withoff et al, 1994). M symbolizes the DNA marker (molecular weight of
the bands from top to bottom: 517 bp, 453 bp, 394 bp and 298 bp)Topoisomerase II levels in ovarian cancer 751
British Journal of Cancer (1999) 79(5/6), 748–753 © Cancer Research Campaign 1999
After scanning the signals densitometrically, the results were
expressed as a percentage of the value obtained for tumour 1. The
results are also shown in Table 2. Topo-IIa protein levels range
from 1% to 109%, with a mean value of 40%. The mean Topo-IIb
protein level was 40% (range 3–100%). Topo-II activities were
also expressed relative to the result obtained for tumour 1. The
results are summarized in the last column of Table 2. Using the
decatenation assay, varying Topo-II activities were found (mean
79%, range 14–183%).
Correlations between several parameters
The results obtained for the tumours with a TVI ³ 50% were used
to search for correlations between the results of the various assays.
In Figure 3, some of the relevant data are shown graphically. Topo-
IIa mRNA levels correlated with Topo-IIa protein level (r = 0.72;
P = 0.01) (Figure 3A), and there was an almost significant correla-
tion between Topo-IIb mRNA level and Topo-IIb protein level
(r = 0.53; P = 0.06) (Figure 3B).
No correlation was found between Topo-IIa protein level and
Topo-II activity (r = 0.35; P = 0.16), however the correlation
between Topo-IIb protein level and Topo-II activity was found to
be significant (r = 0.74; P < 0.01) (Figure 3C). The ratio Topo-
IIb/Topo-IIa did not correlate with Topo-II activity (r = 0.33; P =
0.350). TVI and Topo-IIa or -b protein levels did not correlate for
these ten tumours. Additionally, correlations were found between
the Topo-IIa RT-PCR data and the Topo-IIa Northern blot results
(r = 0.83; P = 0.01) (Figure 3D), and between the Topo-IIa RT-
PCR values and Topo-IIa protein levels (r = 0.68; P = 0.047).
No correlation was found between any clinicopathological
factor and Topo-IIa or -b protein levels nor with Topo-II activity
levels.
Topo-IIa and -b protein levels in non-malignant ovarian
cystadenomas
As Topo-IIb appeared to be an important contributor to overall
Topo-II activity in malignant ovarian tissues, it was decided to
measure Topo-IIa, but more importantly Topo-IIb protein levels,
in eight non-malignant ovarian cystadenomas as well. Previously,
it was shown that Topo-II activity is lower in cystadenoma than in
malignant tissue (Van der Zee et al, 1991). In the eight cyst-
adenoma samples, no Topo-IIa could be detected, and only three
of the eight samples showed detectable Topo-IIb protein bands on
Western blot (results not shown).
DISCUSSION
The first studies on Topo-II levels in human cancers were
performed in haematological malignancies (e.g. Gekeler et al,
1992; Ishikawa et al, 1993; Beck et al, 1994; Kaufmann et al,
1994; Larsson et al, 1994; McKenna et al, 1994). However,
recently more information has become available on Topo-II levels
in solid tumours or in primary cultures of solid tumours (e.g. Kim
et al, 1991; Van der Zee et al, 1991, 1994a,b; Larsson et al, 1994;
Cornarotti et al, 1996; Davies et al, 1996; Sandri et al, 1996;
Martinchick et al, 1997; Turley et al, 1997). The measured levels
have been correlated with clinical response to Topo-II drugs with
varying results.
Possible explanations for the discrepancy between Topo-II
levels and response to chemotherapy in solid tumours might be
that in most studies only one Topo-II parameter was determined
(for instance mRNA level) or the fact that more often only Topo-
IIa levels have been studied, thereby overlooking a possible role
for Topo-IIb. Additionally, in solid tumours, most cells are in
G0/G1 phase in which Topo-IIa levels are very low (Kimura et al,
1994). The possible role of the more recently discovered Topo-IIb
isoenzyme, which is expressed throughout the cell cycle at approx-
imately the same level and which contributes differently (Topo-IIb
is more processive) to overall Topo-II activity (Drake et al, 1989),
may therefore be underestimated. The possible importance of
Topo-IIb in tumours was shown by data obtained from chronic
lymphocytic leukaemias in which Topo-IIa mRNA levels were
often low or even undetectable, whereas Topo-IIb levels were rela-
tively high (Beck et al, 1994).
Previously, it was observed that in untreated human ovarian
carcinomas heterogeneity exists between tumours regarding their
Topo-II activity levels. No relation was found between Topo-IIa
or -b protein levels with Topo-II activity, cleavable complex
formation or cell cycle parameters by Van der Zee et al (1991,
1994a). In contrast, Martinchick et al (1997) did find a correlation
between Topo-IIa protein levels and the cell cycle marker MIB1.
In the present study, Topo-IIa and -b levels were analysed in
untreated ovarian tumours (mRNA, protein and activity). Topo-IIa
and -b mRNA and protein levels could be detected in practically
all tumours.
Considerable variability was already found on mRNA level (see
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Figure 2 Topo-IIb Western blot results showing the tumours described in
Tables 1 and 2 (numbering of the tumours as in these tables)
Figure 3 This figure shows some of the correlations described in the
Results section graphically. Only the results found for tumours with a
TVI ³ 50% are shownTable 2), which may result from differences in transcriptional
regulation or from gene dosage effects.
For the quantification of Topo-IIa mRNA, a very sensitive RT-
PCR assay has become available recently (Withoff et al, 1994).
This assay was used to determine Topo-IIa mRNA levels in some
of the samples in order to validate the feasibility of using this assay
on tumour material. The results obtained with this assay correlate
with Topo-IIa Northern and Western blot results. These findings
indicate that the RT-PCR assay is a powerful tool for determining
Topo-IIa mRNA levels in patient samples quantitatively, and may
be advantageous when only small amounts of tumour are available.
The Topo-IIa Northern blotting data correlated significantly
with Topo-IIa Western blot results, indicating that both techniques
may be used to quantify Topo-IIa levels. For Topo-IIb mRNA,
and protein levels, an almost significant correlation was found.
These results are in contrast with results obtained for six breast
cancer cell lines, in which no correlation between mRNA and
protein level could be found for neither Topo-IIa nor Topo-IIb
(Houlbrook et al, 1995). Whether these differences are due to
differences in tumour type (it was shown that Topo-IIa and Topo-
IIb mRNA levels vary in different tumour types; D’Andrea et al,
1995) or to the fact that Houlbrook et al (1995) studied cell lines,
whereas in the present study tumours are examined, is unclear.
A possible relationship between the expression of each isozyme
and Topo-II activity was not investigated by Houlbrook et al
(1995).
In the ovarian tumour samples measured in this study, Topo-IIb
protein levels correlate significantly with Topo-II activity levels,
whereas Topo-IIa protein levels do not. This finding is in agree-
ment with the assumption that in solid tumours, in which most
cells are in G0/G1 phase, Topo-IIa levels are low. Topo-IIb levels
seem to be stable during different phases of the cell cycle. The
results suggest that Topo-IIb may present a target for
chemotherapy of ovarian cancer. However, a possible contribution
of Topo-IIa to Topo-II activity cannot be ruled out completely,
especially because the possibility of post-translational modifica-
tions of both isozymes has not been investigated in this study.
Additionally, Martinchick et al (1997) have shown that certain
tumours contain a high percentage of Topo-IIa-positive cells.
However, the relationship between Topo-IIa staining and Topo-II
activity was not investigated by these authors. The results obtained
for the eight cystadenomas suggest that Topo-IIa as well as Topo-
IIb protein levels are up-regulated in most ovarian cancer tissues
when compared with non-malignant ovarian cystadenomas.
On the contrary, Cornarotti et al (1996) showed that Topo-IIa
mRNA levels were increased in malignant over benign or normal
ovarian tissues, but Topo-IIb mRNA levels were not. However,
these authors mentioned that comparison between malignant and
benign or normal tissue was troubled by the fact that the majority
of their non-malignant samples consisted of stromal tissue.
Cornarotti et al (1996) also measured only one Topo-II parameter
(mRNA, but not protein levels nor overall Topo-II activity).
When Topo-IIb contributes importantly to Topo-II activity in
ovarian cancer development, Topo-IIb-specific chemotherapy
might be useful in treatment of this type of cancer. The possible
importance of Topo-IIb as an anti-cancer drug target was also
suggested by Sandri et al (1996) and Turley et al (1997), who
described that the b-isoform is more widely expressed than the a-
isoform in several non-ovarian tumour types. At present, no Topo-
IIb-specific drugs are known, although dramatic decreases in
Topo-IIb levels seem to contribute to mitoxantrone resistance in
several resistant cell lines (Harker et al, 1995; Withoff et al, 1996).
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